<DOC>
	<DOCNO>NCT02222155</DOCNO>
	<brief_summary>The aim trial test safety efficacy two dose regimen complement C5a receptor CCX168 patient anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis ( AAV ) . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Clinical Trial Evaluate Safety Efficacy CCX168 ANCA-Associated Vasculitis</brief_title>
	<detailed_description>Complement 5a receptor C5aR ( CD88 ) involve pathogenesis anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis . This randomized , double-blind , placebo-controlled Phase 2 study evaluate safety efficacy C5aR inhibitor CCX168 subject ANCA-associated vasculitis . The aim trial test safety efficacy two dose regimen complement C5a receptor CCX168 patient anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis ( AAV ) .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Antibodies , Antineutrophil Cytoplasmic</mesh_term>
	<criteria>Clinical diagnosis granulomatosis polyangiitis ( Wegener 's ) , microscopic polyangiitis renal limited vasculitis Male female subject , age least 18 year , new relapse AAV treatment cyclophosphamide rituximab would require Use adequate contraception , least three month , administration study medication require Positive indirect immunofluorescence ( IIF ) test PANCA CANCA , positive ELISA test antiproteinase3 ( PR3 ) antimyeloperoxidase ( MPO ) screen Have least one `` major '' item , least 3 item , least 2 renal item Birmingham Vasculitis Activity Score ( BVAS ) version 3 Estimated glomerular filtration rate ( eGFR ) â‰¥ 20 mL per minute Severe disease determine rapidly progressive glomerulonephritis , alveolar hemorrhage , hemoptysis , rapidonset mononeuritis multiplex central nervous system involvement Any multisystem autoimmune disease Medical history coagulopathy bleed disorder Received cyclophosphamide within 12 week prior screen ; azathioprine , mycophenolate mofetil , methotrexate time screening , drug must withdraw prior receive cyclophosphamide rituximab dose Day 1 Received intravenous corticosteroid , &gt; 3000 mg methylprednisolone equivalent , within 12 week prior screen Received oral daily dose corticosteroid 10 mg prednisoneequivalent 6 week continuously prior screen visit Received rituximab Bcell antibody within 52 week screen 26 week provide B cell reconstitution occur ; receive antitumor necrosis factor ( TNF ) treatment , abatacept , alemtuzumab , intravenous immunoglobulin ( IVIg ) , belimumab , tocilizumab , plasma exchange within 12 week prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>complement</keyword>
	<keyword>vasculitis</keyword>
	<keyword>C5aR</keyword>
</DOC>